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Abstract
Objective
To investigate whether longer-term antibiotic treatment improves cognitive performance in
patients with persistent symptoms attributed to Lyme borreliosis.
Methods
Data were collected during the Persistent Lyme Empiric Antibiotic Study Europe (PLEASE)
trial, a randomized, placebo-controlled study. Study participants passed performance-validity
testing (measure for detecting suboptimal effort) and had persistent symptoms attributed to
Lyme borreliosis. All patients received a 2-week open-label regimen of intravenous ceftriaxone
before the 12-week blinded oral regimen (doxycycline, clarithromycin/hydroxychloroquine,
or placebo). Cognitive performance was assessed at baseline and after 14, 26, and 40 weeks
with neuropsychological tests covering the cognitive domains of episodic memory, attention/
working memory, verbal fluency, speed of information processing, and executive function.
Results
Baseline characteristics of patients enrolled (n = 239) were comparable in all treatment groups.
After 14 weeks, performance on none of the cognitive domains differed significantly between
the treatment arms (p = 0.49–0.82). At follow-up, no additional treatment effect (p =
0.35–0.98) or difference between groups (p = 0.37–0.93) was found at any time point. Patients
performed significantly better in several cognitive domains at weeks 14, 26, and 40 compared to
baseline, but this was not specific to a treatment group.
Conclusions
A 2-week treatment with ceftriaxone followed by a 12-week regimen of doxycycline or
clarithromycin/hydroxychloroquine did not lead to better cognitive performance compared to
a 2-week regimen of ceftriaxone in patients with Lyme disease–attributed persistent symptoms.
ClinicalTrials.gov identifier
NCT01207739.
Classification of evidence
This study provides Class II evidence that longer-term antibiotics in patients with borreliosis-
attributed persistent symptoms does not increase cognitive performance compared to shorter-
term antibiotics.
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Many patients who experience persistent symptoms that are
attributed to Lyme borreliosis complain of cognitive problems
such as memory loss, word-finding difficulties, and concen-
tration problems.1,2 However, previous studies have failed to
show significant correlations between subjective memory
complaints and objective test performances in patients with
Lyme borreliosis and other patients.3–6 This makes assessing
neurocognitive function with objective neuropsychological
tests important.
Several small studies have investigated the neurocognitive
performance of patients with Lyme disease compared to healthy
participants. Most found a worse performance in the patient
group.6–13 Deficits observed in patients with persistent symp-
toms attributed to Lyme disease are best typified as a combi-
nation of reduced processing speed and memory problems.9
To date, it is unknownwhether the cognitive problems reported
by patients with persistent Lyme disease–attributed symptoms
are due to an insufficiently treated low-grade Borrelia burgdorferi
infection, remnants of past infection, or incorrect attribution
to Lyme borreliosis. Although most guidelines recommend
antimicrobial therapy for amaximumof 2 to 4weeks,14,15 others
recommend longer-term antibiotic treatment.16
Previous studies have not been conclusive in proving the effects
of longer-term antibiotic therapy on cognition.5,17–20 Further-
more, the trials performed were small (n = 129 and n = 37).5,17
The present study, the largest to date, was performed to eval-
uate the effect of prolonged antimicrobial treatment compared
to shorter-term treatment on neurocognitive function in
patients with symptoms attributed to Lyme borreliosis.
Methods
Study design and participants
The data for this neurocognitive study were collected as sec-
ondary outcomes of the Persistent Lyme Empiric Antibiotic
Study Europe (PLEASE), a multicenter, placebo-controlled,
double-blind randomized clinical trial that was performed
in the Netherlands at 2 locations (Sint Maartenskliniek and
Radboud University Medical Center). From October 2010
through June 2013, patients were enrolled in this trial. The
study design and protocol, inclusion and exclusion criteria,21
and main outcomes were previously published.22 Patients
with ongoing symptoms such as musculoskeletal pain, neu-
ralgia, sensory disturbances, or cognitive complaints were
included if they also had B burgdorferi immunoglobulin (Ig)
G or IgM antibodies or if the complaints were temporally
linked to an erythema migrans or otherwise proven symp-
tomatic Lyme borreliosis.
Standard protocol approvals, registrations,
and patient consents
The local ethics committee has approved the PLEASE
protocol (CMO region Arnhem-Nijmegen, 2009/187,
NL27344.091.09). All participants provided written informed
consent. The trial was registered with ClinicalTrials.gov
(NCT01207739).
Randomization and masking
Computerized randomization distributed patients into 3 groups
in a 1:1:1 ratio. The randomization was balanced by mini-
mization for duration of symptoms (<1 or ≥1 year), age (<40
or ≥40 years), sex, and baseline RAND-36 Health Status In-
ventory Global Health Composite score.23 An independent
web manager entered the randomization list, consisting of
consecutive medication numbers, into a secured web-based
database. None of the participants or personnel involved in
the trial (apart from the web manager and study pharmacist)
were aware of the assignments to study groups.
Classification of evidence
The primary research question is whether longer-term anti-
biotic treatment with 2 weeks of ceftriaxone followed by 12
weeks of doxycycline or clarithromycin/hydroxychloroquine
improves cognitive performance in patients with persistent
symptoms attributed to Lyme borreliosis compared to shorter-
term antibiotic treatment with 2 weeks of ceftriaxone. This trial
provides Class II evidence that longer-term treatment does not
lead to additional improvement.
Intervention
All patients were treated with open-label intravenous cef-
triaxone daily for 2 weeks. After completion, patients started
on a blinded and randomized 12-week oral regimen of doxy-
cycline, clarithromycin-hydroxychloroquine, or placebo. The
study drugs and placebo had an identical appearance. More
details on the intervention have been provided in the study
protocol of the PLEASE trial.21
Procedures
Cognitive performance was assessed at baseline, after end of
treatment (EOT) at 14 weeks, at 26 weeks, and at 40 weeks
with an extensive neuropsychological test battery covering
the 5 major cognitive domains: episodic memory, attention/
working memory, fluency, speed of information processing,
and executive function. We measured episodic memory with
the Rey Auditory Verbal Learning Test, attention/working
memory with the Digit Span Test, language with the Category
Fluency Test, and speed of information processing with the
Trail Making Test Part A, the average speed of cards I and
II from the Stroop Color-Word Test, and the Symbol-Digit
Substitution Test. We assessed executive function with the
Glossary
EOT = end of treatment; Ig = immunoglobulin; PLEASE = Persistent Lyme Empiric Antibiotic Study Europe.
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Trail Making Test Interference Score (Part B/Part A) and
the Stroop Interference Score (card III/average of cards
I and II). The raw test scores were standardized into z scores
by use of the pooled mean of baseline scores of the entire
study sample. The compound score for each cognitive domain
was obtained by calculating the mean of the z scores for tests
making up that domain. Higher scores represent better per-
formance. Further details on the neuropsychological assessment
Figure 1 Flowchart
.
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Table 1 Baseline characteristicsa
Characteristic
Ceftriaxone + doxycycline
(n = 72)
Ceftriaxone + clarithromycin/
hydroxychloroquine (n = 86)
Ceftriaxone +
placebo (n = 81)
Female sex, n (%) 33 (46) 37 (43) 39 (48)
Age (mean ± SD), y 48.3 (12.6) 47.5 (13.0) 50.3 (9.9)
White, n (%) 70 (97) 86 (100) 81 (100)
Current symptoms, n (%)b
Arthralgia 67 (93) 77 (90) 72 (89)
Musculoskeletal pain 61 (85) 69 (80) 63 (78)
Sensory disturbances 50 (69) 67 (78) 65 (81)
Neuralgia 6 (8) 12 (14) 14 (17)
Neurocognitive symptoms 63 (88) 72 (84) 72 (89)
Fatigue 70 (97) 82 (95) 76 (94)
Duration of symptoms, median (IQR), y 2.7 (1.3–7.6) 2.8 (1.4–5.5) 2.3 (0.9–6.2)
History of Lyme disease, n (%)b
Tick bite 39 (55) 43 (51) 48 (60)
Erythema migransc 21 (29) 22 (26) 24 (30)
Acrodermatitis chronica atrophicansd 0 (0) 1 (1) 1 (1)
Borrelia meningoradiculitise 1 (1) 8 (9) 4 (5)
Previous use of antimicrobial treatment
Yes, n (%) 64 (89) 77 (90) 73 (90)
Duration, median (IQR), d 40 (28–56) 30 (21–44) 31 (28–55)
Education level, n (%)f
Low (≤8 y of education) 1 (1.4) 0 (0) 0 (0)
Average (9–11 y of education) 39 (54.9) 40 (46.5) 34 (42.5)
High (≥12 y of education) 31 (43.7) 46 (53.5) 46 (57.5)
Employment,b n (%)
Working 37 (51.4) 58 (67.4) 59 (73.8)h
Student 3 (4.2) 5 (5.8) 2 (2.5)
Disabled or on sick leave 29 (40.3) 28 (32.6) 24 (29.6)
Retired 9 (12.5) 6 (7.0) 7 (9.2)
Cognitive domain compound score,g mean (95% CI)
Episodic memory −0.08 (−0.29 to 0.12) 0.06 (−0.12 to 0.24) 0.19 (0.02 to 0.37)
Attention/working memory −0.11 (−0.35 to 0.13) 0.26 (0.06 to 0.46) 0.06 (−0.17 to 0.29)
Verbal fluency −0.09 (−0.31 to 0.13) −0.01 (−0.22 to 0.20) 0.18 (−0.06 to 0.41)
Speed of information processing 0.00 (−0.20 to 0.19) 0.12 (−0.04 to 0.28) 0.10 (−0.08 to 0.27)
Executive function −0.02 (−0.21 to 0.17) 0.04 (−0.14 to 0.23) 0.11 (−0.06 to 0.27)
Abbreviations: CI = confidence interval; IQR = interquartile range.
a Between-group differences were analyzed with χ2 tests for proportions, analysis of variance for continuous variables, and Fisher exact test for small
numbers. Kruskal-Wallis tests were used for ordinal and not normally distributed data.
b Categories are not mutually exclusive.
c Temporally related: physician-confirmed diagnosis, maximum 4 months before onset of symptoms.
d Temporally related: biopsy or physician-confirmed diagnosis, maximum 4 months before onset of symptoms.
e Temporally related: diagnosis by intrathecal Borrelia immunoglobulin G synthesis, maximum 4 months before onset of symptoms.
f Education was assessed in accordance with the Dutch education system.30
g The z scores were computed from the pooledmean of baseline scores of the entire study sample. For each cognitive domain, a compound scorewas derived
by computing the mean of the z scores for tests making up that domain. Higher scores represent better performance.
h p < 0.05.
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have been published previously in a report on our protocol.21
Furthermore, we administered the Amsterdam Short Term
Memory Test at baseline to identify participants who displayed
suboptimal effort affecting performance validity. This test only
appears to be a difficult task; even patients with brain damage
can perform well.24 Poor performance on this task indicates
suboptimal mental effort. The cutoff score for this performance
validity test is 85 points (maximum score 90), with a sensitivity
of 86% and a specificity of 87%. Because we aimed to obtain an
optimal specificity (i.e., >90%), we included only patients
scoring ≥83 points (with a specificity of 93%) in the analyses to
exclude participants who displayed suboptimal effort.24,25
Statistical analysis
In this study, we report secondary outcomes of the main trial,
the PLEASE study. The analyses include only patients whowere
randomly assigned to a study group, received at least 1 dose of
ceftriaxone (modified intention-to-treat population), and dis-
played sufficient performance validity at baseline (Amsterdam
Short TermMemory Test score ≥83). For descriptive purposes,
we also classified individuals at baseline as having a clinically
impaired cognitive performance using Multivariate Normative
Comparisons26 based on a large Dutch normative data set from
the Advanced Neuropsychological Diagnostic Infrastructure.27
We compared the 3 study groups at week 14 (EOT) with
analysis of covariance, including baseline domain score as
a covariate. Missing data at week 14 were imputed if they
occurred in <5% of the cases28 with the mean of the treat-
ment group at that assessment moment. We performed linear
mixed models to estimate the duration of the potential in-
tervention effect, including all 3 posttreatment assessments (14,
26, and 40 weeks). All models contained the baseline value of
the dependent variable, time, study group treatment, and time-
by-treatment interaction.
The α level was set at 0.05 (2 tailed), and 95% confidence
intervals are reported when appropriate. For pairwise com-
parisons of the 5 domains among the 3 study groups at different
endpoints, Bonferroni correction was used (by adjusting α to
0.01) to reduce the probability of family-wise (type I) error.
Sensitivity analyses included all analyses without imputation.
SPSS software version 22 was used to perform the statistical
analyses.
Data availability
Anonymized data, related documents such as study protocol,
and statistical analysis will be shared by request from any
qualified investigator for 5 years after the date of publication.
Results
Of the 281 patients randomized, 85% (n = 239) displayed
sufficient performance validity on the cognitive tests at baseline
(figure 1). No baseline differences were found between the
Table 2 Neuropsychological performance at EOT (14 weeks)a
Cognitive domain
Ceftriaxone + doxycycline
(n = 72)
Ceftriaxone + clarithromycin/
hydroxychloroquine (n = 86)
Ceftriaxone +
placebo (n = 81) p Value
Episodic memory 0.70
Mean z score (95% CI) 0.19 (0.03 to 0.35) 0.27 (0.13 to 0.41) 0.27 (0.12 to 0.42)
Difference with placebo (95% CI) −0.08 (−0.34 to 0.18) 0.00 (−0.25 to 0.25) —
Attention/working memory 0.65
Mean z score (95% CI) 0.21 (0.05 to 0.37) 0.16 (0.01 to 0.30) 0.25 (0.10 to 0.40)
Difference with placebo (95% CI) −0.04 (−0.30 to 0.22) −0.10 (−0.35 to 0.16) —
Verbal fluency 0.60
Mean z score (95% CI) 0.18 (0.02 to 0.35) 0.24 (0.09 to 0.39) 0.13 (−0.03 to 0.28)
Difference with placebo (95% CI) 0.06 (−0.22 to 0.34) 0.11 (−0.16 to 0.38) —
Speed of information processing 0.49
Mean z score (95% CI) 0.25 (0.15 to 0.36) 0.30 (0.21 to 0.39) 0.34 (0.24 to 0.44)
Difference with placebo (95% CI) −0.09 (−0.26 to 0.09) −0.04 (−0.20 to 0.13) —
Executive function 0.82
Mean z score (95% CI) 0.14 (−0.01 to 0.28) 0.13 (0.00 to 0.27) 0.19 (0.05 to 0.32)
Difference with placebo (95% CI) −0.05 (−0.30 to 0.19) −0.05 (−0.29 to 0.18) —
Abbreviations: CI = confidence interval; EOT = end of treatment.
a Between-group differences in characteristics were analyzed with analysis of covariance adjusted for baseline domain score.
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3 treatment groups, including baseline neuropsychological
performance (table 1), apart from the percentage of patients
with a job, which significantly differed between groups. At
baseline, 7 of 239 patients were classified as having a clini-
cally impaired cognitive performance compared to Dutch
normative data.
The neuropsychological performance (i.e., the mean z score
per domain) at EOT (14 weeks), corrected for baseline per-
formance and sex, did not significantly differ between treat-
ment groups for any of the domains, with p values ranging
from 0.49 to 0.82 (table 2).
Figure 2 shows the mean performance per group for each
neuropsychological domain over time. The differences between
the various time points compared to baseline are depicted in
table 3. The performance on 2 domains, episodic memory and
speed of information, significantly improved between baseline
and EOT in all randomization groups. Similarly, at 26 and
40 weeks, several domains showed higher scores compared
to baseline.
However, no additional long-term treatment effects were seen
in mixed-model analyses (the difference between the treat-
ment arms did not change over time) for any of the domains;
p values ranged from 0.35 to 0.98 for the time-by-treatment
interaction. No significant difference was found between the
3 treatment groups at any time point during follow-up in
neuropsychological performance either (p values ranging from
0.37 to 0.93). All sensitivity analyses yielded results similar to
those of the main analyses. Several post hoc analyses were also
done. Subset analyses with patients who had symptoms for
<1 year (n = 46) did not show a significant difference be-
tween treatment groups. Excluding patients who did not
Figure 2 Mean z score (95% confidence interval) per treatment group per neuropsychological domain at all study visits
(A) Episodic memory, (B) working memory, (C) fluency, (D) speed of information processing, and (E) executive function.
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report subjective cognitive complaints at baseline (n = 32)
did not yield different results, nor did post hoc analyses on
the subgroup of patients with severe subjective symptoms as
measured by the Cognitive Failures Questionnaire.29 With
a cutoff value for the Cognitive FailuresQuestionnaire set at 44,
111 patients were considered to have severe neurocognitive
symptoms. Finally, subgroup analyses including only patients
who had a high burden of symptoms (i.e., those who were on
sick leave or disability support, n = 81) also did not show
a significant difference between placebo and antimicrobial
treatment groups. Using analysis of covariance, with sick leave/
disability and baseline cognitive function as covariates, we
found no significant difference between treatment groups.
Discussion
This study showed that prolonged antibiotic treatment for 3
months in patients with persistent Lyme borreliosis–attributed
symptoms does not have an additional beneficial effect on
cognitive performance compared to short-term treatment.
Previous case series have suggested a significant cognitive im-
provement on most domains after antibiotic treatment.18,19
Two randomized controlled treatment trials have also demon-
strated significant improvement of objective test scores after
treatment compared to baseline performance.5,17 However, no
significant differences were found between those receiving
antibiotics and those receiving placebo in 1 trial,5 and the other
trial did not show sustainable effects of antibiotic treatment on
cognition.17 In our trial, mixed-model analyses showed no dif-
ference over time. Cognitive improvements were found at weeks
14, 26, and 40 only when the separate domains were directly
compared with baseline, and changes over time were at most in
the small to moderate range. Because an improvement was seen
in all treatment groups, including the placebo control group, the
observed changes appear to be neither clinically relevant nor
treatment specific. The global difference found over timemay be
the result of a placebo effect, nonspecific practice effects,
spontaneous improvement over time, or a combination of these.
The present study is the largest trial performed to date. It was
specifically designed prospectively to study treatment outcomes,
Table 3 Treatment effect at different endpoints (14, 26, and 40 weeks compared to baseline)
Cognitive domain
Week 14 vs baseline Week 26 vs baseline Week 40 vs baseline
Difference in mean
z score (SEM) p Valuea
Difference in mean
z score (SEM) p Valuea
Difference in mean
z score (SEM) p Valuea
Episodic memory
Ceftriaxone + doxycycline 0.16 (0.08) 0.056 0.26 (0.07) <0.01 0.20 (0.08) 0.015
Ceftriaxone + clarithromycin 0.22 (0.08) <0.01 0.27 (0.07) <0.01 0.18 (0.07) 0.017
Ceftriaxone + placebo 0.19 (0.07) <0.01 0.14 (0.08) 0.090 0.19 (0.08) 0.013
Attention/working memory
Ceftriaxone + doxycycline 0.18 (0.08) 0.031 0.26 (0.07) <0.01 0.32 (0.10) <0.01
Ceftriaxone + clarithromycin 0.04 (0.08) 0.589 0.11 (0.07) 0.132 0.23 (0.09) 0.015
Ceftriaxone + placebo 0.19 (0.07) 0.012 0.29 (0.09) <0.01 0.37 (0.09) <0.01
Verbal fluency
Ceftriaxone + doxycycline 0.19 (0.09) 0.033 0.32 (0.08) <0.01 0.29 (0.09) <0.01
Ceftriaxone + clarithromycin 0.20 (0.09) 0.025 0.39 (0.09) <0.01 0.46 (0.11) <0.01
Ceftriaxone + placebo 0.09 (0.08) 0.245 0.12 (0.10) 0.209 0.35 (0.09) <0.01
Speed of information processing
Ceftriaxone + doxycycline 0.19 (0.05) <0.01 0.33 (0.05) <0.01 0.46 (0.06) <0.01
Ceftriaxone + clarithromycin 0.22 (0.05) <0.01 0.41 (0.06) <0.01 0.50 (0.07) <0.01
Ceftriaxone + placebo 0.26 (0.05) <0.01 0.40 (0.06) <0.01 0.47 (0.07) <0.01
Executive function
Ceftriaxone + doxycycline 0.11 (0.07) 0.1290 0.22 (0.08) 0.010 0.17 (0.09) 0.075
Ceftriaxone + clarithromycin 0.10 (0.08) 0.1884 0.20 (0.10) 0.044 0.20 (0.09) 0.031
Ceftriaxone + placebo 0.11 (0.09) 0.2013 0.10 (0.08) 0.185 0.17 (0.07) 0.019
a Bonferroni correction was applied, i.e., α was adjusted to 0.01.
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including cognitive performance, using a strictly controlled
design.21,22 In addition, our study is the first to take suboptimal
cognitive effort into account in the neuropsychological as-
sessment by selecting only patients who displayed sufficient
performance validity. Kaplan et al.5 have investigated the
personality traits of participants and investigated symptom
validity to some extent by examining the patients’ ability to
present a false impression using the Minnesota Multiphasic
Personality Inventory-2. However, that does not compare to
our way of taking suboptimal cognitive effort explicitly into
account through performance validity testing.
A limitation of our study may relate to missing values. To
reduce the influence of missing values, mixed-model analyses
were performed. In these analyses, no significant differences
between groups on any of the domains were observed.
While a ceiling effect may be considered, because only a few-
patients were overall cognitively impaired at baseline, none of
the raw scores were at or near ceiling for any of the tests at
various endpoints. The mean performances per test were typ-
ically in the midrange between the minimally and maximally
possible scores, leaving sufficient room for improvement.
The fact that we did not include only patients with subjective
cognitive complaints could be seen as another limitation. How-
ever, our patient population is representative of the real-life
population of patients with Lyme borreliosis, improving the ex-
ternal validity. Moreover, only 32 of 280 patients did not report
subjective cognitive complaints at baseline. Post hoc analyses
excluding those 32 patients did not yield different results;
i.e., there was no significant difference between groups at EOT.
Finally, because the study was not specifically powered for
detecting neuropsychological test outcomes, the results must
be seen as preliminary.
Future studies on treatment of cognitive function in individuals
with Lyme borreliosis may specifically focus on the small group
of patients with objectively impaired cognitive performance.
Our study suggests that cognitive performance as assessed by
validated tests does not improve with longer antibiotic treat-
ment compared to shorter-term treatment in patients with
persistent symptoms attributed to Lyme borreliosis.
Acknowledgment
The authors thank Dr. Joost A. Agelink van Rentergem,
University of Amsterdam, for his assistance with the Advanced
Neuropsychological Diagnostics Infrastructure analyses.
Study funding
Funded by the Netherlands National Organization for Sci-
entific Research (ID ZonMw 171002304).
Disclosure
The authors report no disclosures relevant to the manuscript.
Go to Neurology.org/N for full disclosures.
Publication history
Received by Neurology August 24, 2018. Accepted in final form
November 21, 2018.
Appendix Authors
Name Location Role Contribution
Anneleen
Berende, MD
Radboud
University Medical
Center, Nijmegen,
the Netherlands
Author Drafting/revising the
manuscript for content,
including medical
writing for content;
study concept/design;
analysis/interpretation
of data; acquisition of
data; statistical
analysis; study
supervision/
coordination
Hadewych
J.M. ter
Hofstede,
MD, PhD
Radboud
University Medical
Center, Nijmegen
Author Revising the
manuscript for content,
including medical
writing for content;
study concept/design;
acquisition of data;
study supervision/
coordination; obtaining
funding
Fidel J. Vos,
MD, PhD
Sint
Maartenskliniek,
Nijmegen
Author Revising the
manuscript for content,
including medical
writing for content;
acquisition of data
Michiel L.
Vogelaar,
MSc
Radboud
University Medical
Center, Nijmegen
Author Revising the
manuscript for content,
including medical
writing for content;
analysis/interpretation
of data; acquisition of
data; statistical analysis
Henrie¨t van
Middendorp,
PhD
Leiden University,
Leiden, the
Netherlands
Author Revising the
manuscript for content,
including medical
writing for content;
statistical analysis
Andrea W.M.
Evers, PhD
Leiden University,
Leiden
Author Revising the
manuscript for content,
including medical
writing for content;
study concept/design;
study supervision/
coordination
Roy P.C.
Kessels, PhD
Radboud
University,
Nijmegen
Author Drafting/revising the
manuscript for content,
including medical
writing for content;
study concept/design;
analysis/interpretation
of data; statistical
analysis; study
supervision/
coordination
Bart Jan
Kullberg, MD,
PhD
Radboud
University Medical
Center, Nijmegen
Author Revising the
manuscript for
content, including
medical writing for
content; study
concept/design;
acquisition of data;
study supervision/
coordination;
obtaining funding
e1454 Neurology | Volume 92, Number 13 | March 26, 2019 Neurology.org/N
References
1. Aucott JN, Rebman AW, Crowder LA, Kortte KB. Post-treatment Lyme disease
syndrome symptomatology and the impact on life functioning: is there something
here? Qual Life Res 2013;22:75–84.
2. Logigian EL, Kaplan RF, Steere AC. Chronic neurologic manifestations of Lyme
disease. N Engl J Med 1990;323:1438–1444.
3. Bermeo-Ovalle A. Do we know what we think we know? Reconciling subjective
complaints and objective cognitive testing in older adults with epilepsy. Epilepsy Curr
2016;16:230–231.
4. Galioto R, Blum AS, Tremont G. Subjective cognitive complaints versus objective
neuropsychological performance in older adults with epilepsy. Epilepsy Behav 2015;
51:48–52.
5. Kaplan RF, Trevino RP, Johnson GM, et al. Cognitive function in post-treatment
Lyme disease: do additional antibiotics help? Neurology 2003;60:1916–1922.
6. Ravdin LD, Hilton E, Primeau M, Clements C, Barr WB. Memory functioning in
Lyme borreliosis. J Clin Psychiatry 1996;57:282–286.
7. Eikeland R, Ljostad U, Mygland A, Herlofson K, Lohaugen GC. European neuro-
borreliosis: neuropsychological findings 30 months post-treatment. Eur J Neurol
2012;19:480–487.
8. Gaudino EA, Coyle PK, Krupp LB. Post-Lyme syndrome and chronic fatigue
syndrome: neuropsychiatric similarities and differences. Arch Neurol 1997;54:
1372–1376.
9. Keilp JG, Corbera K, Slavov I, Taylor MJ, Sackeim HA, Fallon BA. WAIS-III andWMS-
III performance in chronic Lyme disease. J Int Neuropsychol Soc 2006;12:119–129.
10. Krupp LB, Masur D, Schwartz J, et al. Cognitive functioning in late Lyme borreliosis.
Arch Neurol 1991;48:1125–1129.
11. Pollina DA, Sliwinski M, Squires NK, Krupp LB. Cognitive processing speed in Lyme
disease. Neuropsychiatry Neuropsychol Behav Neurol 1999;12:72–78.
12. Shadick NA, Phillips CB, Logigian EL, et al. The long-term clinical outcomes of Lyme
disease: a population-based retrospective cohort study. Ann Intern Med 1994;121:
560–567.
13. Westervelt HJ, McCaffrey RJ. Neuropsychological functioning in chronic Lyme dis-
ease. Neuropsychol Rev 2002;12:153–177.
14. Mygland A, Ljøstad U, Fingerle V, Rupprecht T, Schmutzhard E, Steiner I. EFNS
guidelines on the diagnosis and management of European Lyme neuroborreliosis. Eur
J Neurol 2010;17, 8–4.
15. Wormser GP, Dattwyler RJ, Shapiro ED, et al. The clinical assessment, treatment, and
prevention of Lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical
practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis
2006;43:1089–1134.
16. Cameron DJ, Johnson LB, Maloney EL. Evidence assessments and guideline recom-
mendations in Lyme disease: the clinical management of known tick bites, erythema
migrans rashes and persistent disease. Expert Rev Anti Infect Ther 2014;12:1103–1135.
17. Fallon BA, Keilp JG, Corbera KM, et al. A randomized, placebo-controlled trial of
repeated IV antibiotic therapy for Lyme encephalopathy. Neurology 2008;70:992–1003.
18. Halperin JJ, Pass HL, Anand AK, Luft BJ, Volkman DJ, Dattwyler RJ. Nervous system
abnormalities in Lyme disease. Ann NY Acad Sci 1988;539:24–34.
19. Logigian EL, Kaplan RF, Steere AC. Successful treatment of Lyme encephalopathy
with intravenous ceftriaxone. J Infect Dis 1999;180:377–383.
20. Klempner MS, Hu LT, Evans J, et al. Two controlled trials of antibiotic treatment in
patients with persistent symptoms and a history of Lyme disease. N Engl J Med 2001;
345:85–92.
21. Berende A, ter Hofstede HJ, Donders AR, et al. Persistent Lyme Empiric Antibiotic
Study Europe (PLEASE): design of a randomized controlled trial of prolonged an-
tibiotic treatment in patients with persistent symptoms attributed to Lyme borreliosis.
BMC Infect Dis 2014;14:543.
22. Berende A, ter Hofstede HJ, Vos FJ, et al. Randomized trial of longer-term therapy for
symptoms attributed to Lyme disease. N Engl J Med 2016;374:1209–1220.
23. Hays RD. RAND-36 Health Status Inventory. San Antonio: Psychological Corp; 1998.
24. Schagen S, Schmand B, de Sterke S, Lindeboom J. Amsterdam Short-Term Memory
Test: a new procedure for the detection of feigned memory deficits. J Clin Exp
Neuropsychol 1997;19:43–51.
25. Schmand B, Lindeboom J. Amsterdam Short Term Memory Test: Manual. Oxford,
UK: Hogrefe; 2005.
26. Agelink van Rentergem JA, Murre JM, Huizenga HM. Multivariate normative com-
parisons using an aggregated database. PLoS One 2017;12:e0173218.
27. de Vent NR, Agelink van Rentergem JA, Schmand BA, Murre JM, Consortium A,
Huizenga HM. Advanced Neuropsychological Diagnostics Infrastructure (ANDI):
a normative database created from control datasets. Front Psychol 2016;7:1601.
28. Graham JW. Missing data analysis: making it work in the real world. Annu Rev
Psychol 2009;60:549–576.
29. Broadbent DE, Cooper PF, FitzGerald P, Parkes KR. The Cognitive Failures Ques-
tionnaire (CFQ) and its correlates. Br J Clin Psychol 1982;21(pt 1):1–16.
30. Hochstenbach J, Mulder T, van Limbeek J, Donders R, Schoonderwaldt H. Cognitive
decline following stroke: a comprehensive study of cognitive decline following stroke.
J Clin Exp Neuropsychol 1998;20:503–517.
Neurology.org/N Neurology | Volume 92, Number 13 | March 26, 2019 e1455
DOI 10.1212/WNL.0000000000007186
2019;92;e1447-e1455 Published Online before print February 22, 2019Neurology 
Anneleen Berende, Hadewych J.M. ter Hofstede, Fidel J. Vos, et al. 
Effect of prolonged antibiotic treatment on cognition in patients with Lyme borreliosis
This information is current as of February 22, 2019
Services
Updated Information &
 http://n.neurology.org/content/92/13/e1447.full
including high resolution figures, can be found at:
References
 http://n.neurology.org/content/92/13/e1447.full#ref-list-1
This article cites 28 articles, 2 of which you can access for free at: 
Subspecialty Collections
 http://n.neurology.org/cgi/collection/neuropsychological_assessment
Neuropsychological assessment
 lled_consort_agreement
http://n.neurology.org/cgi/collection/clinical_trials_randomized_contro
Clinical trials Randomized controlled (CONSORT agreement)
 http://n.neurology.org/cgi/collection/class_ii
Class II
 http://n.neurology.org/cgi/collection/bacterial_infections
Bacterial infections
following collection(s): 
This article, along with others on similar topics, appears in the
  
Permissions & Licensing
 http://www.neurology.org/about/about_the_journal#permissions
its entirety can be found online at:
Information about reproducing this article in parts (figures,tables) or in
  
Reprints
 http://n.neurology.org/subscribers/advertise
Information about ordering reprints can be found online:
ISSN: 0028-3878. Online ISSN: 1526-632X.
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.. All rights reserved. Print
1951, it is now a weekly with 48 issues per year. Copyright Copyright © 2019 The Author(s). Published by 
® is the official journal of the American Academy of Neurology. Published continuously sinceNeurology 
